A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection

Journal of Infection

Volumn 46, Issue 1, 2003, Pages 56-59

  Mc Manus, Terry E ^a,b   Moore, J E ^a   Crowe, M ^a   Dunbar, K ^a   Elborn, J S ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BODY MASS; BURKHOLDERIA CEPACIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FLOW RATE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; INFORMATION PROCESSING; LEUKOCYTE COUNT; SUPERINFECTION; UNITED KINGDOM; VITAL CAPACITY;

EID: 0142123574     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2001.1077     Document Type: Article

References (15)

1. Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ. Inflammatory markers in cystic fibrosis. Respir Med 1991; 85: 139-145.
2. Valletta EA, Rigo A, Bonazzi L, Zanolla L, Mastella G. Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis. Acta Paediatr 1992; 81: 227-230.
3. Peckham D, Crouch S, Humphreys H, Lobo B, Tse A, Knox AJ. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Thorax 1994; 49: 803-807.
4. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1764-1769.
5. Hughes JE, Stewart J, Barclay GR, Govan JRW. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun 1997; 65: 4281-4287.
6. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35-51.
7. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas Aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-549.
8. Hutchison ML, Bonell C, Poxton IR, Govan RW. Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. Immun Med Microbiol 2000; 27: 73-77.
9. Bosso JA, Walker KB. Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis. Clin Pharm 1988; 7: 897-901.
10. Kumar A, Wofford-McQueen R, Gordon RC. In vitro activity of multiple antimicrobial combinations against Pseudomonas cepacia isolates. Chemotherapy 1989; 35: 246-253.
11. Chin NX, Neu HC. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Diagn Microbiol Infect Dis 1989; 12: 343-349.
12. Kumar A, Wofford-McQueen R, Gordon RC. Ciprofloxacin, imipenem and Rifampicin: in-vitro synergy of two and three drug combinations against Pseudomonas cepacia. J Antimicrob Chemother 1989; 23: 831-835.
13. Simon DM, Koeing G, Trenhome GM. Differences in release of tumour necrosis factor from TPH-1 cells stimulated by filtration of antibiotic killed Escherichia coli. J Infect Dis 1991; 164: 800-802.
14. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, Wilson R. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998; 12: 820-824.
15. Konstan MW, Hillard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.